Validation of the Bleeding Risk and Mortality in the Use of Warfarin and Antiplatelet Agents in Hemodialysis Patients
Not Applicable
- Conditions
- End stage renal failure on hemodialysis
- Registration Number
- JPRN-UMIN000023916
- Lead Sponsor
- Sagami Junkanki Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who did not give informed consent, and who were lost to follow up due to a transfer to other institutions.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method